# Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine

> **NCT05303584** · PHASE4 · COMPLETED · sponsor: **Jiangsu Province Centers for Disease Control and Prevention** · enrollment: 362 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Ad5-nCoV-IH
- **BIOLOGICAL:** Ad5-nCoV-IM
- **BIOLOGICAL:** CoronaVac

## Key facts

- **NCT ID:** NCT05303584
- **Lead sponsor:** Jiangsu Province Centers for Disease Control and Prevention
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-23
- **Primary completion:** 2022-06-20
- **Final completion:** 2023-05-31
- **Target enrollment:** 362 (ACTUAL)
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05303584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05303584, "Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05303584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*